JP2008526991A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526991A5 JP2008526991A5 JP2007551416A JP2007551416A JP2008526991A5 JP 2008526991 A5 JP2008526991 A5 JP 2008526991A5 JP 2007551416 A JP2007551416 A JP 2007551416A JP 2007551416 A JP2007551416 A JP 2007551416A JP 2008526991 A5 JP2008526991 A5 JP 2008526991A5
- Authority
- JP
- Japan
- Prior art keywords
- bendamustine
- formulation
- concentration
- amount
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 81
- 229960002707 bendamustine Drugs 0.000 claims 77
- 229960001215 bendamustine hydrochloride Drugs 0.000 claims 48
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 claims 45
- 238000000034 method Methods 0.000 claims 34
- 239000000203 mixture Substances 0.000 claims 29
- 238000009472 formulation Methods 0.000 claims 26
- 239000012931 lyophilized formulation Substances 0.000 claims 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical group CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 16
- 238000004108 freeze drying Methods 0.000 claims 13
- 239000003960 organic solvent Substances 0.000 claims 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 9
- 239000000047 product Substances 0.000 claims 9
- 238000001035 drying Methods 0.000 claims 8
- 239000006185 dispersion Substances 0.000 claims 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 6
- 239000007857 degradation product Substances 0.000 claims 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 5
- 229930195725 Mannitol Natural products 0.000 claims 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 5
- 239000008176 lyophilized powder Substances 0.000 claims 5
- 235000010355 mannitol Nutrition 0.000 claims 5
- 239000000594 mannitol Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000000087 stabilizing effect Effects 0.000 claims 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- 229940034982 antineoplastic agent Drugs 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 238000013475 authorization Methods 0.000 claims 3
- GVLZDNWNOBSNEN-UHFFFAOYSA-N ethyl 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoate Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(=O)OCC)=NC2=C1 GVLZDNWNOBSNEN-UHFFFAOYSA-N 0.000 claims 3
- 239000012467 final product Substances 0.000 claims 3
- 229960004592 isopropanol Drugs 0.000 claims 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 238000000354 decomposition reaction Methods 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000007710 freezing Methods 0.000 claims 2
- 230000008014 freezing Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960004926 chlorobutanol Drugs 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940088679 drug related substance Drugs 0.000 claims 1
- VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- HOQADATXFBOEGG-UHFFFAOYSA-N isofenphos Chemical compound CCOP(=S)(NC(C)C)OC1=CC=CC=C1C(=O)OC(C)C HOQADATXFBOEGG-UHFFFAOYSA-N 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- OCDRLZFZBHZTKQ-NMUBGGKPSA-N onetine Chemical compound C[C@@H](O)[C@@]1(O)C[C@@H](C)[C@@](C)(O)C(=O)OC\C2=C\CN(C)CC[C@@H](OC1=O)C2=O OCDRLZFZBHZTKQ-NMUBGGKPSA-N 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64435405P | 2005-01-14 | 2005-01-14 | |
| US11/330,868 US8436190B2 (en) | 2005-01-14 | 2006-01-12 | Bendamustine pharmaceutical compositions |
| PCT/US2006/001308 WO2006076620A2 (en) | 2005-01-14 | 2006-01-13 | Bendamustine pharmaceutical compositions for lyophilisation |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012231759A Division JP5726833B2 (ja) | 2005-01-14 | 2012-10-19 | ベンダムスチン製薬学的組成物 |
| JP2012231760A Division JP5688195B2 (ja) | 2005-01-14 | 2012-10-19 | ベンダムスチン製薬学的組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008526991A JP2008526991A (ja) | 2008-07-24 |
| JP2008526991A5 true JP2008526991A5 (https=) | 2009-10-15 |
Family
ID=36678237
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007551416A Pending JP2008526991A (ja) | 2005-01-14 | 2006-01-13 | ベンダムスチン製薬学的組成物 |
| JP2012231760A Expired - Lifetime JP5688195B2 (ja) | 2005-01-14 | 2012-10-19 | ベンダムスチン製薬学的組成物 |
| JP2012231759A Expired - Lifetime JP5726833B2 (ja) | 2005-01-14 | 2012-10-19 | ベンダムスチン製薬学的組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012231760A Expired - Lifetime JP5688195B2 (ja) | 2005-01-14 | 2012-10-19 | ベンダムスチン製薬学的組成物 |
| JP2012231759A Expired - Lifetime JP5726833B2 (ja) | 2005-01-14 | 2012-10-19 | ベンダムスチン製薬学的組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (9) | US8436190B2 (https=) |
| EP (2) | EP1863452B1 (https=) |
| JP (3) | JP2008526991A (https=) |
| KR (4) | KR101918188B1 (https=) |
| CN (1) | CN102078305B (https=) |
| AR (1) | AR052877A1 (https=) |
| AU (1) | AU2006204817B2 (https=) |
| BR (1) | BRPI0606332A2 (https=) |
| CA (1) | CA2593582A1 (https=) |
| EA (1) | EA013324B1 (https=) |
| ES (1) | ES2405611T3 (https=) |
| IL (1) | IL184394A0 (https=) |
| MX (1) | MX2007008562A (https=) |
| MY (1) | MY157661A (https=) |
| NO (1) | NO343659B1 (https=) |
| NZ (1) | NZ556435A (https=) |
| SG (1) | SG158870A1 (https=) |
| TW (1) | TWI380830B (https=) |
| WO (1) | WO2006076620A2 (https=) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| HRP20140338T1 (hr) | 2005-07-25 | 2014-06-20 | Emergent Product Development Seattle, Llc | Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20 |
| US20090082416A1 (en) * | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched bendamustine |
| EP2219605B1 (en) * | 2007-10-09 | 2015-08-19 | US Worldmeds LLC | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
| AR072777A1 (es) * | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| EP2365003A1 (en) * | 2008-04-11 | 2011-09-14 | Emergent Product Development Seattle, LLC | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| EP2326306A1 (en) | 2008-09-25 | 2011-06-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| WO2010056733A1 (en) * | 2008-11-13 | 2010-05-20 | Indiana University Research And Technology Corporation | Combined use of bendamustine, doxorubicin and bortezomib for the treatment of multiple myeloma |
| EP2367542B1 (en) * | 2008-12-03 | 2014-01-01 | Astellas Deutschland GmbH | Oral dosage forms of bendamustine |
| UA107186C2 (xx) * | 2008-12-03 | 2014-12-10 | Тверді форми дозування бендамустину | |
| NZ594010A (en) * | 2009-01-15 | 2013-08-30 | Cephalon Inc | Novel forms of bendamustine free base |
| WO2010085377A2 (en) | 2009-01-23 | 2010-07-29 | Crystal Biopharmaceutical Llc | Hydroxamic acid derivatives |
| WO2010097700A1 (en) | 2009-02-25 | 2010-09-02 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| MX2011011109A (es) * | 2009-04-28 | 2011-11-18 | Cephalon Inc | Formulaciones orales de bendamustina. |
| WO2010144675A1 (en) | 2009-06-10 | 2010-12-16 | Plus Chemicals Sa | Polymorphs of bendamustine hcl and processes for preparation thereof |
| US8389558B2 (en) * | 2009-07-20 | 2013-03-05 | Supratek Pharma Inc. | Bendamustine amphiphilic anionic compositions |
| US20110015245A1 (en) * | 2009-07-20 | 2011-01-20 | Valery Alakhov | Bendamustine amphiphilic cationic compositions |
| PL3158991T3 (pl) * | 2010-01-28 | 2021-09-27 | Eagle Pharmaceuticals, Inc. | Preparaty bendamustyny |
| WO2011103150A2 (en) * | 2010-02-18 | 2011-08-25 | Cephalon, Inc. | Lyophilized preparations of bendamustine |
| US20130202693A1 (en) | 2010-06-02 | 2013-08-08 | Astellas Deutschland Gmbh | Oral Dosage Forms of Bendamustine |
| JO3659B1 (ar) | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| MX2013000373A (es) * | 2010-07-13 | 2013-02-15 | Cephalon Inc | Metodos mejorados para la esterilizacion de bendamustina. |
| US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| WO2012103226A2 (en) * | 2011-01-25 | 2012-08-02 | Dr. Reddy's Laboratories Ltd. | Bendamustine formulations |
| CN107837395A (zh) * | 2011-02-09 | 2018-03-27 | 葛兰素史密斯克莱有限责任公司 | 冻干制剂 |
| US20120237492A1 (en) | 2011-02-18 | 2012-09-20 | Kythera Biopharmaceuticals, Inc. | Treatment of submental fat |
| AU2011376953B2 (en) * | 2011-09-13 | 2017-08-24 | Pharmacyclics Llc | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
| EP2760842B1 (en) | 2011-09-26 | 2016-11-16 | Fresenius Kabi Oncology Ltd | An improved process for the preparation of bendamustine hydrochloride |
| WO2013102920A1 (en) | 2011-11-18 | 2013-07-11 | Astron Research Limited | Stable lyophilized formulation of bendamustine |
| US20130210878A1 (en) * | 2012-01-24 | 2013-08-15 | Innopharma, Inc. | Bendamustine compositions and methods therefore |
| AR092790A1 (es) * | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | Derivados bencimidazolicos del acido hidroxamico |
| WO2013117969A1 (en) | 2012-02-06 | 2013-08-15 | Fresenius Kabi Oncology Ltd. | Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis |
| EP2814487A4 (en) * | 2012-02-14 | 2015-07-15 | Eagle Pharmaceuticals Inc | FORMULAS FROM BENDAMUSTIN |
| CA2867295C (en) | 2012-03-20 | 2020-08-11 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| PL2827863T3 (pl) | 2012-03-20 | 2019-07-31 | Eagle Pharmaceuticals, Inc. | Ciekła kompozycja do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania |
| WO2013148919A1 (en) | 2012-03-30 | 2013-10-03 | The Regents Of The University Of Colorado, A Body Corporate | Treatment of multiple myeloma |
| US9801859B2 (en) * | 2012-09-18 | 2017-10-31 | Innopharma Licensing, Llc | Bendamustine formulations |
| BR112015010501A2 (pt) * | 2012-11-12 | 2017-07-11 | Ignyta Inc | composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada |
| DK2732811T3 (en) | 2012-11-19 | 2016-03-21 | Oncotec Pharma Produktion Gmbh | A process for preparing a freeze-dried composition |
| CN103860482B (zh) * | 2012-12-12 | 2016-08-24 | 海口市制药厂有限公司 | 一种盐酸苯达莫司汀冻干粉针剂的制备方法、其产品及用途 |
| CN103040769A (zh) * | 2013-02-05 | 2013-04-17 | 南京碧迪可医药科技有限公司 | 一种稳定的诺卡沙星粉针冻干剂 |
| EP2958554B1 (en) | 2013-02-19 | 2018-06-06 | Synthon BV | Stable compositions of bendamustine |
| WO2014170769A2 (en) * | 2013-04-15 | 2014-10-23 | Shilpa Medicare Limited | Bendamustine lyophilized pharmaceutical compositions |
| ITMI20131013A1 (it) | 2013-06-19 | 2014-12-20 | Chemi Spa | Formulazioni liofilizzate di bendamustina cloridrato |
| JP2016153374A (ja) * | 2013-06-25 | 2016-08-25 | シンバイオ製薬株式会社 | 炎症性疾患を治療又は予防するための医薬組成物 |
| CN103351347A (zh) * | 2013-07-29 | 2013-10-16 | 东南大学 | 盐酸苯达莫司汀杂质dce的制备方法 |
| ES2957541T3 (es) | 2013-08-27 | 2024-01-22 | Vasilios Voudouris | Composiciones farmacéuticas de bendamustina |
| US20150087681A1 (en) * | 2013-09-25 | 2015-03-26 | Pranav Patel | Bendamustine HCL Stable Lyophilized Formulations |
| US20160235717A1 (en) * | 2013-10-11 | 2016-08-18 | Luitpold Pharmaceuticals, Inc. | Bendamustine pharmaceutical compositions |
| IN2014CH00151A (https=) * | 2014-01-13 | 2015-07-17 | Hetero Research Foundation | |
| CA2941632C (en) | 2014-03-13 | 2023-10-24 | Vasilios VOUDOURIS | Bendamustine solid dispersions and continuous infusion |
| US20150320774A1 (en) | 2014-05-09 | 2015-11-12 | AuroMedics Pharma LLC | Formulations of cyclophosphamide liquid concentrate |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| EP2985038A1 (en) | 2014-08-12 | 2016-02-17 | Azad Pharma AG | Lyophilized API preparation |
| US10342769B2 (en) | 2014-11-14 | 2019-07-09 | Navinta Iii Inc | Carmustine pharmaceutical composition |
| US9603930B2 (en) | 2014-12-04 | 2017-03-28 | Navinta, Llc | Liquid bendamustine formulation |
| CA3003746A1 (en) * | 2015-11-04 | 2017-05-11 | Kythera Biopharmaceuticals, Inc. | Treatments of accumulated fat with deoxycholic acid and salts thereof |
| US11826466B2 (en) | 2016-08-31 | 2023-11-28 | Navinta, Llc | Bendamustine solution formulations |
| US10905677B2 (en) | 2016-08-31 | 2021-02-02 | Navinta, Llc | Bendamustine solution formulations |
| AU2016426574B2 (en) | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| US10688222B2 (en) | 2016-11-21 | 2020-06-23 | Warsaw Orthopedic, Inc. | Lyophilized moldable implants containing an oxysterol |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| ES3055021T3 (en) | 2018-08-17 | 2026-02-09 | Hospira Australia Pty Ltd | Liquid bendamustine pharmaceutical compositions |
| US11730815B2 (en) | 2018-11-26 | 2023-08-22 | Good Health, Llc | Stable liquid pharmaceutical compositions comprising bendamustine |
| CN113365624A (zh) | 2018-12-18 | 2021-09-07 | 萌蒂制药国际有限公司 | 用于治疗淋巴瘤或t-细胞恶性疾病的化合物 |
| US11406598B2 (en) | 2019-09-20 | 2022-08-09 | Nivagen Pharmaceuticals, Inc. | Lyophilized compositions of phenobarbital sodium salt |
| CN110638765A (zh) * | 2019-11-08 | 2020-01-03 | 江苏食品药品职业技术学院 | 一种卡莫司汀冻干工艺 |
| US20240148696A1 (en) | 2022-10-25 | 2024-05-09 | Softkemo Pharma Inc. | Lyophilized bendamustine-cyclodextrin composition |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1354952U (https=) | ||||
| DE159289C (https=) | 1903-10-08 | 1905-03-16 | ||
| DD80967A (https=) | ||||
| DE80967C (https=) | ||||
| DE34727C (de) | Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue | Verfahren zur direkten Gewinnung metallischen Bleis | ||
| DD34727A1 (de) | 1963-12-21 | 1964-12-28 | Dietrich Krebs | Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren |
| YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| US4012448A (en) | 1976-01-15 | 1977-03-15 | Stanford Research Institute | Synthesis of adriamycin and 7,9-epiadriamycin |
| DD159289A1 (de) | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
| DD159877A1 (de) | 1981-06-12 | 1983-04-13 | Wolfgang Krueger | Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure |
| IT1153974B (it) * | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
| US4537883A (en) | 1982-11-12 | 1985-08-27 | Mead Johnson & Company | Lyophilized cyclophosphamide |
| US5227374A (en) | 1982-11-12 | 1993-07-13 | Mead Johnson & Company | Lyophilized cyclophosphamide |
| US4659699A (en) | 1983-08-22 | 1987-04-21 | Cetus-Ben Venue Therapeutics | Process for freeze drying cyclophosphamide |
| US5183746A (en) | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
| NO873860L (no) * | 1986-10-31 | 1988-05-02 | Asta Pharma Ag | Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling. |
| US5204335A (en) | 1986-10-31 | 1993-04-20 | Asta Pharma Aktiengesellschaft | Ifosfamide lyophilisate and process for its preparation |
| DE3907079A1 (de) | 1988-03-19 | 1989-09-28 | Asta Pharma Ag | Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung |
| EP0334083B1 (de) | 1988-03-19 | 1991-07-24 | ASTA Pharma Aktiengesellschaft | Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung |
| US5036060A (en) | 1988-07-25 | 1991-07-30 | Fujisawa Usa, Inc. | Cyclophosphamide |
| CA2001552C (en) | 1988-11-14 | 1997-07-22 | The Upjohn Company | Cyclophosphamide - sodium bicarbonate lyophilizates |
| US5066647A (en) | 1989-04-20 | 1991-11-19 | Erbamont, Inc. | Cyclophosphamide - alanine lyophilizates |
| DD293808A5 (de) | 1990-04-23 | 1991-09-12 | Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De | Verfahren zur herstellung von (5-[bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl(2)ethansaeurealkylestern |
| US5268368A (en) | 1991-05-17 | 1993-12-07 | Erbamont, Inc. | Cyclophosphamide--amino acid lyophilizates |
| US5227373A (en) | 1991-10-23 | 1993-07-13 | Bristol-Myers Squibb Co. | Lyophilized ifosfamide compositions |
| US5192743A (en) | 1992-01-16 | 1993-03-09 | Genentech, Inc. | Reconstitutable lyophilized protein formulation |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5418223A (en) | 1993-05-20 | 1995-05-23 | Erbamont, Inc. | Method for lyophilization of cyclophosphamide and product |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US5741523A (en) | 1993-10-27 | 1998-04-21 | Pharmacia & Upjohn Company | Stabilized prostaglandin E1 |
| US5561121A (en) * | 1993-11-09 | 1996-10-01 | American Cyanamid Company | Stable lyophilized thiotepa composition |
| JPH10503768A (ja) * | 1994-08-02 | 1998-04-07 | メルク シヤープ エンド ドーム リミテツド | アゼチジン、ピロリジンおよびピペリジン誘導体 |
| US5955504A (en) | 1995-03-13 | 1999-09-21 | Loma Linda University Medical Center | Colorectal chemoprotective composition and method of preventing colorectal cancer |
| DE19529057B4 (de) | 1995-08-08 | 2007-12-13 | Baxter Healthcare S.A. | Ifosfamid-Lyophilisat-Zubereitungen |
| JPH11511463A (ja) | 1995-08-31 | 1999-10-05 | スミスクライン・ビーチャム・コーポレイション | インターロイキン変換酵素およびアポプトーシス |
| DE69624081T2 (de) | 1995-12-20 | 2003-06-12 | Agouron Pharmaceuticals, Inc. | Matrix-metalloprotease Inhibitoren |
| US6261537B1 (en) * | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
| US6034256A (en) | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| US20040072889A1 (en) | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
| US6077850A (en) | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| DE69929440T2 (de) | 1998-07-09 | 2006-08-17 | Cephalon, Inc. | Zusammensetzungen zur behandlung chronischer lymphatischer leukämie |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| US5972912A (en) | 1998-12-17 | 1999-10-26 | S.P. Pharmaceuticals | Method for lyophilizing ifosfamide |
| US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| US6380210B1 (en) | 1999-04-02 | 2002-04-30 | Neurogen Corporation | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
| US6545034B1 (en) | 1999-07-23 | 2003-04-08 | The Regents Of The University Of California | Use of etodolac for the treatment of chronic lymphocytic leukemia |
| DE10016077A1 (de) | 2000-03-31 | 2001-12-13 | Cellcontrol Biomedical Lab Gmb | Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen |
| US20040152672A1 (en) | 2000-08-09 | 2004-08-05 | Carson Dennis A. | Indole compounds useful for the treatment of cancer |
| CA2431319A1 (en) | 2000-12-11 | 2002-06-20 | Hiroto Bando | Pharmaceutical composition having an improved water solubility |
| WO2002048142A1 (en) | 2000-12-11 | 2002-06-20 | Takeda Chemical Industries, Ltd. | Medicinal compositions having improved absorbability |
| KR100679990B1 (ko) * | 2001-10-15 | 2007-02-08 | 헤모텍 게엠베하 | 재협착증의 방지를 위한 스텐트의 코팅 |
| US6613927B1 (en) | 2002-02-08 | 2003-09-02 | American Pharmaceutical Partners, Inc. | Sterile lyophilized ifosfamide and associated methods |
| DE10306724A1 (de) | 2002-02-28 | 2003-09-18 | G O T Therapeutics Gmbh | Vesikuläre Verkapselung von Bendamustin |
| US6780324B2 (en) * | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
| EP1485720B1 (en) | 2002-03-22 | 2008-03-12 | Ludwig Maximilians Universität | Cytocapacity test |
| EP1354952A1 (en) | 2002-04-17 | 2003-10-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| EP1495124A2 (en) | 2002-04-17 | 2005-01-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| DE10393059D2 (de) | 2002-05-09 | 2005-05-04 | Hemoteq Gmbh | Verbindungen und Verfahren zur hemokompatiblen Beschichtung von Oberflächen |
| AU2003258061A1 (en) | 2002-08-02 | 2004-02-23 | Salmedix, Inc. | Therapeutic inhibitionof protein kinases in cancer cells |
| NZ540318A (en) | 2002-10-31 | 2007-09-28 | Umd Inc | Therapeutic compositions for drug delivery to and through covering epithelia |
| DE10304403A1 (de) | 2003-01-28 | 2004-08-05 | Röhm GmbH & Co. KG | Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung |
| EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| CA2516191A1 (en) | 2003-02-14 | 2004-09-02 | Salmedix, Inc | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers |
| CN1829514A (zh) * | 2003-07-25 | 2006-09-06 | 惠氏公司 | Cci－779冻干制剂 |
| RU2346996C2 (ru) | 2004-06-29 | 2009-02-20 | ЮРОПИЭН НИКЕЛЬ ПиЭлСи | Усовершенствованное выщелачивание основных металлов |
| JP2008519047A (ja) | 2004-11-05 | 2008-06-05 | セフアロン・インコーポレーテツド | 癌処置 |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| EP2326306A1 (en) | 2008-09-25 | 2011-06-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
-
2006
- 2006-01-12 US US11/330,868 patent/US8436190B2/en active Active
- 2006-01-13 AR ARP060100158A patent/AR052877A1/es not_active Application Discontinuation
- 2006-01-13 KR KR1020177022494A patent/KR101918188B1/ko not_active Expired - Lifetime
- 2006-01-13 WO PCT/US2006/001308 patent/WO2006076620A2/en not_active Ceased
- 2006-01-13 TW TW095101383A patent/TWI380830B/zh not_active IP Right Cessation
- 2006-01-13 CN CN201010621759.3A patent/CN102078305B/zh not_active Expired - Lifetime
- 2006-01-13 MY MYPI20060159A patent/MY157661A/en unknown
- 2006-01-13 EP EP06718390A patent/EP1863452B1/en not_active Revoked
- 2006-01-13 NZ NZ556435A patent/NZ556435A/en unknown
- 2006-01-13 EP EP12191786A patent/EP2574334A1/en not_active Withdrawn
- 2006-01-13 SG SG201000184-0A patent/SG158870A1/en unknown
- 2006-01-13 EA EA200701511A patent/EA013324B1/ru unknown
- 2006-01-13 KR KR1020167021645A patent/KR20160098530A/ko not_active Ceased
- 2006-01-13 BR BRPI0606332-2A patent/BRPI0606332A2/pt not_active Application Discontinuation
- 2006-01-13 KR KR1020077018503A patent/KR101648495B1/ko not_active Expired - Lifetime
- 2006-01-13 CA CA002593582A patent/CA2593582A1/en not_active Abandoned
- 2006-01-13 MX MX2007008562A patent/MX2007008562A/es active IP Right Grant
- 2006-01-13 ES ES06718390T patent/ES2405611T3/es not_active Expired - Lifetime
- 2006-01-13 JP JP2007551416A patent/JP2008526991A/ja active Pending
- 2006-01-13 AU AU2006204817A patent/AU2006204817B2/en not_active Expired
- 2006-01-13 KR KR1020187014177A patent/KR20180056804A/ko not_active Ceased
-
2007
- 2007-07-03 IL IL184394A patent/IL184394A0/en active IP Right Review Request
- 2007-07-18 NO NO20073722A patent/NO343659B1/no unknown
-
2012
- 2012-10-18 US US13/654,898 patent/US8461350B2/en not_active Expired - Lifetime
- 2012-10-19 JP JP2012231760A patent/JP5688195B2/ja not_active Expired - Lifetime
- 2012-10-19 JP JP2012231759A patent/JP5726833B2/ja not_active Expired - Lifetime
- 2012-12-19 US US13/719,409 patent/US8895756B2/en not_active Expired - Lifetime
- 2012-12-19 US US13/719,379 patent/US8609863B2/en not_active Expired - Lifetime
-
2013
- 2013-08-19 US US13/969,724 patent/US8791270B2/en not_active Expired - Lifetime
-
2014
- 2014-01-31 US US14/169,961 patent/US20140148490A1/en not_active Abandoned
-
2015
- 2015-09-04 US US14/845,564 patent/US20150374671A1/en not_active Abandoned
-
2018
- 2018-06-19 US US16/012,417 patent/US20180296534A1/en not_active Abandoned
-
2019
- 2019-11-26 US US16/695,624 patent/US20200237726A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526991A5 (https=) | ||
| JP6869941B2 (ja) | ある含有量のマイトマイシンｃを有する凍結乾燥医薬組成物を製造する方法 | |
| EA013324B1 (ru) | Фармацевтические композиции бендамустина, предназначенные для лиофилизации | |
| WO2013117969A1 (en) | Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis | |
| CN102869363A (zh) | 冻干的块状制剂 | |
| CN110876259B (zh) | 注射用组合物 | |
| JP2014525449A5 (https=) | ||
| US20140142153A1 (en) | Bendamustine formulations | |
| JP6542888B2 (ja) | カルムスチン医薬組成物 | |
| JP2016521731A (ja) | 抗がん剤を含む安定な水溶性医薬組成物 | |
| CN103655486B (zh) | 西罗莫司微乳颗粒及其制备方法和应用 | |
| WO2016116882A2 (en) | Novel compositions of carfilzomib | |
| CN108926534B (zh) | 改性kgm卵磷脂载nmn透皮醇质体、制剂及其制备工艺与应用 | |
| JP6165986B2 (ja) | ボルテゾミブを含む医薬組成物 | |
| EP3821920A1 (en) | Combination for endoscopic surgery | |
| EP3166595B1 (en) | Micronized insulin, micronized insulin analogues, and methods of manufacturing the same | |
| AU2021206890B2 (en) | High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same | |
| CN103751109A (zh) | 替格瑞洛干混悬剂及其制备方法 | |
| CN1706501A (zh) | 亲脂性药物环糊精包合物的制备方法 | |
| CN1820748A (zh) | 一种左旋奥硝唑冻干粉针注射剂 | |
| WO2020025069A1 (zh) | 一种水化环磷酰胺冻干组合物的方法及其产品 | |
| KR20130070556A (ko) | 유기용매 무함유 젬시타빈 수용액 조성물 | |
| WO2014170769A2 (en) | Bendamustine lyophilized pharmaceutical compositions | |
| CN121925253A (zh) | 冻干的羟基脲甲基酰基富烯 | |
| CN120078751A (zh) | 一种晶型稳定的盐酸多奈哌齐口溶膜剂及其制备方法 |